Cite
HARVARD Citation
Kishimoto, M. et al. (2023). Upadacitinib for moderate-to-severe atopic dermatitis, in adults and adolescents 12 years and older: review of international and Japanese populations. Expert review of clinical immunology. pp. 19-35. [Online].